|
Telmisartan is an angiotensin receptor blockers (ARB) that has a
longer half-life and penetrates the blood-brain barrier
unlike Benicar(Olmesartan) or Valsartan
described in articles, letters and emails by the Marshall's (marshallprotocol.com).
Telmisartan appears to be distinctly superior for CFIDS.
- Once a day dosage is practical, twice a day preferred
- Reaches the Brain
- As dosage increases, the concentration in the body increases faster than
the dosage (odd - but desirable characteristic)
- Less blood pressure drop than Benicar.
- Since it crosses the brain barrier like
candesartan, it
should improve migraines
and may impact cognitive functions.
There are no studies on it's impact on inflammation (but every other one has
been -- with all reducing it).
See: Comparison of ARBs and
Dosing Protocols for more information.
| |
Home
Original 2001 WebSite as PDF for download
|
